Botox has been the reigning, if unofficial, monarch of cosmetic procedures for nearly a decade. But its claim to the beauty throne is being rattled this week by a study in which patients thought another brand of botulinum toxin, the Botox competitor Dysport, smoothed their “crow’s feet” wrinkles a bit better.
In a randomized, double-blind face-off funded by the makers of Dysport, patients received injections of Botox on one side of the face and injections of Dysport on the other. The substances were applied to the muscles that close the eyelids.
After 30 days, researchers said, two-thirds of the patients said they preferred the Dysport side of their face; one-third chose the Botox side.
However, when judging photos of the wrinkles on a five-point scale, the difference between how both participants and researchers rated Dysport and Botox sides of the face was statistically significant only when the eye muscles were contracted, not when at rest. The findings were published online Monday in the journal Archives of Facial Plastic Surgery.